"Omics" and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas.

Elda Tagliabue,Manuela Campiglio

doi:10.3389/fonc.2014.00334

Elda Tagliabue, Manuela Campiglio

Open Access

https://doi.org/10.3389/fonc.2014.00334

Copy DOI

Abstract

"Omics" and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas.

Highlights

While clinical results indicate the benefit of HER2-targeted treatment, the fact remains that this therapy administered according to current FDA/EMEA-approved protocols can only cure about 50% of patients with HER2-positive breast carcinoma [1]
2–4% present activating mutations within the kinase domain of ERBB2 analogous to those detected in EGFR and never coexisting with EGFR, KRAS, or ALK alterations [3,4,5]
Heterogeneity of HER2 amplification must be considered in clinical therapeutic decisions, despite pilot results suggesting that a similar trastuzumab benefit for patients with HER2 amplification, either diffuse or focal [9]

Summary

Introduction

While clinical results indicate the benefit of HER2-targeted treatment, the fact remains that this therapy administered according to current FDA/EMEA-approved protocols can only cure about 50% of patients with HER2-positive breast carcinoma [1]. Molecular alterations of HER2 and its presence on the tumor cell membrane endow this oncoprotein with relevant immunological properties, making it an ideal target antigen for long-term cancer immunoprevention.

Results

Conclusion